Chinese medical authorities have claimed a drug used in Japan to treat new strains of influenza appears to be effective for those infected with the coronavirus, Japan’s state broadcaster NHK reported. Zhang Xinmin, director of China’s National Center for Biotechnology Development, said the favipiravir drug had produced positive outcomes during clinical trials in Wuhan and Shenzen. The report on Tuesday said 340 patients had taken part in the clinical trials. “It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters. Patients treated with the drug, which was developed by a subsidiary of Fujifilm, in Shenzen were found to turn negative for COVID-19 after a median of four days, rather than 11 days for those who were not treated with favipiravir, NHK reported.
